Search

Your search keyword '"Licour M"' showing total 21 results
Start Over Author "Licour M" Search Limiters Full Text
21 results on '"Licour M"'

1. Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R

Author

Filippi, A.R., Bar, J., Chouaid, C., Christoph, D.C., Field, J.K., Fietkau, R., Garassino, M.C., Garrido, P., Haakensen, V.D., Kao, S., Markman, B., McDonald, F., Mornex, F., Moskovitz, M., Peters, S., Sibille, A., Siva, S., van den Heuvel, M., Vercauter, P., Anand, S., Chander, P., Licour, M., de Lima, A.R., Qiao, Y., and Girard, N.

Published
2024
Full Text
View/download PDF

2. Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study

Author

Girard, N, Bar, J, Garrido, P, Garassino, MC, McDonald, F, Mornex, F, Filippi, AR, Smit, HJM, Peters, S, Field, JK, Christoph, DC, Sibille, A, Fietkau, R, Haakensen, VD, Chouaid, C, Markman, B, Hiltermann, TJN, Taus, A, Sawyer, W, Allen, A, Chander, P, Licour, M, Solomon, B, Girard, N, Bar, J, Garrido, P, Garassino, MC, McDonald, F, Mornex, F, Filippi, AR, Smit, HJM, Peters, S, Field, JK, Christoph, DC, Sibille, A, Fietkau, R, Haakensen, VD, Chouaid, C, Markman, B, Hiltermann, TJN, Taus, A, Sawyer, W, Allen, A, Chander, P, Licour, M, and Solomon, B

Abstract

INTRODUCTION: The phase 3 PACIFIC trial established consolidation therapy with durvalumab as standard of care for patients with unresectable, stage III NSCLC and no disease progression after definitive chemoradiotherapy (CRT). The observational PACIFIC-R study assesses the real-world effectiveness of durvalumab in patients from an early access program. Here, we report treatment characteristics and a preplanned analysis of real-world progression-free survival (rwPFS). METHODS: PACIFIC-R (NCT03798535) is an ongoing, international, retrospective study of patients who started durvalumab (intravenously; 10 mg/kg every 2 wk) within an early access program between September 2017 and December 2018. The primary end points are investigator-assessed rwPFS and overall survival (analyzed by Kaplan-Meier method). RESULTS: As of November 30, 2020, the full analysis set comprised 1399 patients from 11 countries (median follow-up duration, 23.5 mo). Patients received durvalumab for a median of 11.0 months. Median rwPFS was 21.7 months (95% confidence interval: 19.1-24.5). RwPFS was numerically longer among patients who received concurrent versus sequential CRT (median, 23.7 versus 19.3 mo) and among patients with programmed cell death-ligand 1 expression greater than or equal to 1% versus less than 1% (22.4 versus 15.6 mo). Overall, 16.5% of the patients had adverse events leading to treatment discontinuation; 9.5% of all patients discontinued because of pneumonitis or interstitial lung disease. CONCLUSIONS: Consolidation durvalumab after definitive CRT was well tolerated and effective in this large, real-world cohort study of patients with unresectable, stage III NSCLC. As expected, rwPFS was longer among patients who received concurrent versus sequential CRT and patients with higher programmed cell death-ligand 1 expression. Nevertheless, favorable rwPFS outcomes were observed regardless of these factors.

Published
2023

3. 58O Real-world overall survival (OS) with durvalumab (D) after chemoradiotherapy (CRT) in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC): Interim analysis from the PACIFIC-R study

Author

Girard, N., primary, Christoph, D.C.C., additional, Garassino, M.C., additional, McDonald, F., additional, Mornex, F., additional, Field, J.K., additional, Fietkau, R., additional, Garrido Lopez, P., additional, Haakensen, V.D., additional, Siva, S., additional, van den Heuvel, M., additional, Bar, J., additional, Chouaid, C., additional, Vercauter, P., additional, Chander, P., additional, Licour, M., additional, Anand, S., additional, de Lima, A.R.M.D., additional, and Filippi, A.R.R., additional

Published
2022
Full Text
View/download PDF

5. 1171MO PACIFIC-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

Author

Girard, N., primary, Smit, H.J.M., additional, Sibille, A., additional, McDonald, F., additional, Mornex, F., additional, Garassino, M.C.C., additional, Filippi, A.R., additional, Peters, S., additional, Field, J.K., additional, Christoph, D.C., additional, Fietkau, R., additional, Haakensen, V.D., additional, Bar, J., additional, Chouaid, C., additional, Bray, V., additional, Kao, S., additional, Sawyer, W., additional, Allen, A., additional, Licour, M., additional, and Garrido, P., additional

Published
2021
Full Text
View/download PDF

6. 79MO PACIFIC-R: Real-world characteristics of unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

Author

McDonald, F., primary, Mornex, F., additional, Garassino, M.C., additional, Filippi, A.R., additional, Christoph, D., additional, Haakensen, V.D., additional, Agbarya, A., additional, Van den Heuvel, M., additional, Vercauter, P., additional, Chouaid, C., additional, Pichon, E., additional, Siva, S., additional, Steinbusch, L., additional, Peretz, I., additional, Solomon, B., additional, Decoster, L., additional, Sawyer, W., additional, Allen, A., additional, Licour, M., additional, and Girard, N., additional

Published
2021
Full Text
View/download PDF

7. 1242P Characteristics of the first 615 patients enrolled in Pacific R: A study of the first real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

Author

Girard, N., primary, Fietkau, R., additional, Garassino, M., additional, Garrido, P., additional, Field, J.K., additional, Peters, S., additional, Smit, H.J.M., additional, Pérol, M., additional, Merle, P., additional, Sibille, A., additional, Markman, B., additional, Bouchaab, H., additional, Moskovitz, M., additional, Schumann, C., additional, Gregorc, V., additional, Klein, A.B., additional, Diaz Perez, I., additional, Sawyer, W., additional, Licour, M., additional, and Christoph, D., additional

Published
2020
Full Text
View/download PDF

9. Predictive markers of immune mediated adverse events and of treatment response in patients treated with durvalumab monotherapy or in combination with tremelimumab (IOPREDI study)

Author

Marabelle, A., primary, Ghiringhelli, F., additional, Ayyoub, M., additional, Tartour, E., additional, Adotevi, O., additional, Loriot, Y., additional, Lambotte, O., additional, Cupissol, D., additional, Damotte, D., additional, Adam, J., additional, Bonvalet, M., additional, Petre Lazar, B., additional, Licour, M., additional, and Chaput, N., additional

Published
2018
Full Text
View/download PDF

10. Effect of Pre-Hospital Ticagrelor During the First 24 h After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction The ATLANTIC-H-24 Analysis

Author

Montalescot, G, van't Hof, AW, Bolognese, L, Cantor, WJ, Cequier, A, Chettibi, M, Collet, JP, Goodman, SG, Hammett, CJ, Huber, K, Janzon, M, Lapostolle, F, Lassen, JF, Licour, M, Merkely, B, Salhi, N, Silvain, J, Storey, RF, ten Berg, JM, Tsatsaris, A, Zeymer, U, Vicaut, E, Hamm, CW, Peñaranda, A.S., and Carson, Andy

Subjects
myocardial infarction, stents, platelets, thrombosis, reperfusion
Abstract

OBJECTIVES The aim of this landmark exploratory analysis, ATLANTIC-H-24, was to evaluate the effects of pre-hospital ticagrelor during the first 24 h after primary percutaneous coronary intervention (PCI) in the ATLANTIC (Administration of Ticagrelor in the cath Lab or in the Ambulance for New ST elevation myocardial infarction to open the Coronary artery) study. BACKGROUND The ATLANTIC trial in patients with ongoing ST-segment elevation myocardial infarction showed that pre-hospital ticagrelor was safe but did not improve pre-PCI coronary reperfusion compared with in-hospital ticagrelor. We hypothesized that the effect of pre-hospital ticagrelor may not have manifested until after PCI due to the rapid transfer time (31 min). METHODS The ATLANTIC-H-24 analysis included 1,629 patients who underwent PCI, evaluating platelet reactivity, Thrombolysis In Myocardial Infarction flow grade 3, >= 70% ST-segment elevation resolution, and clinical endpoints over the first 24 h. RESULTS Following PCI, largest between-group differences in platelet reactivity occurred at 1 to 6 h; coronary reperfusion rates numerically favored pre-hospital ticagrelor, and the degree of ST-segment elevation resolution was significantly greater in the pre-hospital group (median, 75.0% vs. 71.4%; p = 0.049). At 24 h, the composite ischemic endpoint was lower with pre-hospital ticagrelor (10.4% vs. 13.7%; p = 0.039), as were individual endpoints of definite stent thrombosis (p = 0.0078) and myocardial infarction (p = 0.031). All endpoints except death (1.1% vs. 0.2%; p = 0.048) favored pre-hospital ticagrelor, with no differences in bleeding events. CONCLUSIONS The effects of pre-hospital ticagrelor became apparent after PCI, with numerical differences in platelet reactivity and immediate post-PCI reperfusion, associated with reductions in ischemic endpoints, over the first 24 h, whereas there was a small excess of mortality. (Administration of Ticagrelor in the cath Lab or in the Ambulance for New ST elevation myocardial infarction to open the Coronary artery [ATLANTIC, NCT01347580]) (C) 2016 by the American College of Cardiology Foundation.

Published
2016

13. Osimertinib in EGFR T790M positive advanced NSCLC (aNSCLC) – real–life data from the French temporary authorization for use (ATU) program

Author

Planchard, D., primary, Pérol, M., additional, Quantin, X., additional, Cortot, A., additional, Cadranel, J., additional, Schott, R., additional, Dansin, E., additional, Fraboulet, G., additional, Moro-Sibilot, D., additional, Soria, J.-C., additional, Mazieres, J., additional, Moulec, S.L.e., additional, Coudurier, M., additional, Pichon, E., additional, Licour, M., additional, Maribas, D., additional, Gourion, A., additional, Radu, N., additional, Varoqueaux, N., additional, and Chouaid, C., additional

Published
2016
Full Text
View/download PDF

14. Circulating free tumour-derived DNA (ctDNA) to detect EGFR mutation in patients (pts) with advanced NSCLC (aNSCLC): French subset analysis of the ASSESS study

Author

Denis, M.G., primary, Lafourcade, M.P., additional, Le Garff, G., additional, Dayen, C., additional, Falchero, L., additional, Thomas, P., additional, Locher, C., additional, Fraboulet, G., additional, Oliviero, G., additional, Licour, M., additional, Normanno, N., additional, Reck, M., additional, and Molinier, O., additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results